- Home
- APAD vs EDIT Comparison
APAD vs EDIT Comparison
Compare APAD & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APAD
- EDIT
- Stock Information
- Founded
- APAD 2022
- EDIT 2013
- Country
- APAD Hong Kong
- EDIT United States
- Employees
- APAD N/A
- EDIT N/A
- Industry
- APAD
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- APAD
- EDIT Health Care
- Exchange
- APAD Nasdaq
- EDIT Nasdaq
- Market Cap
- APAD 280.7M
- EDIT 269.8M
- IPO Year
- APAD 2025
- EDIT 2016
- Fundamental
- Price
- APAD $9.98
- EDIT $3.19
- Analyst Decision
- APAD
- EDIT Buy
- Analyst Count
- APAD 0
- EDIT 11
- Target Price
- APAD N/A
- EDIT $4.56
- AVG Volume (30 Days)
- APAD 119.2K
- EDIT 3.2M
- Earning Date
- APAD 01-01-0001
- EDIT 10-31-2025
- Dividend Yield
- APAD N/A
- EDIT N/A
- EPS Growth
- APAD N/A
- EDIT N/A
- EPS
- APAD N/A
- EDIT N/A
- Revenue
- APAD N/A
- EDIT $38,901,000.00
- Revenue This Year
- APAD N/A
- EDIT N/A
- Revenue Next Year
- APAD N/A
- EDIT N/A
- P/E Ratio
- APAD N/A
- EDIT N/A
- Revenue Growth
- APAD N/A
- EDIT N/A
- 52 Week Low
- APAD $9.87
- EDIT $0.91
- 52 Week High
- APAD $10.00
- EDIT $4.54
- Technical
- Relative Strength Index (RSI)
- APAD N/A
- EDIT 43.62
- Support Level
- APAD N/A
- EDIT $3.15
- Resistance Level
- APAD N/A
- EDIT $3.87
- Average True Range (ATR)
- APAD 0.00
- EDIT 0.34
- MACD
- APAD 0.00
- EDIT -0.11
- Stochastic Oscillator
- APAD 0.00
- EDIT 7.07
About APAD A Paradise Acquisition Corp. Class A Ordinary Shares
A Paradise Acquisition Corp is a blank check company.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.